Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
AIDS/HIV
100%
South Africa
100%
Human Rotavirus Vaccine
100%
Immunogenicity
100%
RIX4414
100%
Reactogenicity
100%
Rotavirus
42%
South African
28%
Enzyme-linked Immunosorbent Assay (ELISA)
28%
Placebo Groups
28%
Serious Adverse Events
28%
Public Health Risk
14%
Viral Load
14%
Human Immunodeficiency Virus Type 1 (HIV-1)
14%
Placebo
14%
Stool Samples
14%
Immune Response
14%
Developing Countries
14%
Diarrhea
14%
Randomized Placebo-controlled Trial
14%
Human Immunodeficiency Virus Infection
14%
Routine Vaccines
14%
Seroconversion Rate
14%
Mildly Symptomatic
14%
WHO Classification
14%
Prolonged Shedding
14%
Clinical Stage I
14%
Immunodeficiency
14%
CD4 Cell Count
14%
CD4 Percentage
14%
African Infants
14%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Rotavirus Vaccine
100%
Human Rotavirus
100%
Immunogenicity
100%
Rotavirus
37%
Placebo
37%
Adverse Event
25%
Enzyme-Linked Immunosorbent Assay
25%
Diarrhea
12%
Human Immunodeficiency Virus Infection
12%
Human Immunodeficiency Virus 1
12%
Placebo-Controlled Study
12%
Immunoglobulin A
12%
Immune Deficiency
12%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Rotavirus Vaccine
100%
Human Rotavirus
100%
Immunogenicity
100%
Rotavirus
37%
Enzyme-Linked Immunosorbent Assay
25%
Human Immunodeficiency Virus Infection
12%
CD4 Lymphocyte Count
12%
Viral Load
12%
Human Immunodeficiency Virus 1
12%
Immune Response
12%
CD4 Lymphocyte Percentage
12%
Immunoglobulin A
12%
Seroconversion
12%
Immunodeficiency
12%